Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Profile

Rangaswamy Govindarajan

Concepts (127)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colonic Neoplasms
3
2016
158
0.770
 Why?
Anus Neoplasms
1
2018
24
0.590
 Why?
Antineoplastic Combined Chemotherapy Protocols
3
2020
1000
0.510
 Why?
Bone Marrow Neoplasms
1
2015
13
0.500
 Why?
Embolism
1
2015
20
0.500
 Why?
Gene Regulatory Networks
1
2016
106
0.490
 Why?
Carcinoma, Squamous Cell
1
2018
326
0.480
 Why?
Tumor Lysis Syndrome
1
2014
5
0.470
 Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2014
45
0.450
 Why?
Neoplasm Recurrence, Local
1
2018
626
0.440
 Why?
Pyrazoles
1
2014
112
0.430
 Why?
Pyrimidines
1
2014
191
0.420
 Why?
Angiogenesis Inhibitors
2
2006
183
0.410
 Why?
Clinical Trials as Topic
5
2019
488
0.400
 Why?
Actinomycosis
1
2012
10
0.400
 Why?
Biliary Tract Diseases
1
2012
13
0.400
 Why?
Salvage Therapy
1
2013
137
0.400
 Why?
Bile Duct Neoplasms
1
2012
27
0.400
 Why?
Stomach Neoplasms
1
2015
188
0.390
 Why?
Prognosis
6
2019
1979
0.370
 Why?
Gene Expression Profiling
1
2016
1024
0.370
 Why?
Benzenesulfonates
2
2011
10
0.360
 Why?
Middle Aged
12
2020
12648
0.350
 Why?
Carcinoma, Hepatocellular
1
2013
197
0.350
 Why?
Stroke
1
2015
495
0.350
 Why?
Pyridines
2
2011
132
0.330
 Why?
Liver Neoplasms
1
2013
328
0.320
 Why?
Colorectal Neoplasms
2
2003
258
0.310
 Why?
Aged, 80 and over
6
2018
3244
0.290
 Why?
Heparin
1
2007
91
0.270
 Why?
Drug Industry
1
2007
38
0.270
 Why?
Thrombocytopenia
1
2007
82
0.270
 Why?
Communication Barriers
1
2007
31
0.270
 Why?
Hypertensive Encephalopathy
1
2006
3
0.270
 Why?
raf Kinases
1
2006
4
0.270
 Why?
Thiazolidinediones
1
2007
82
0.260
 Why?
Aged
9
2020
9770
0.250
 Why?
Skin
1
2007
385
0.230
 Why?
Anticoagulants
1
2007
254
0.230
 Why?
Thrombosis
1
2007
250
0.230
 Why?
Adult
9
2020
13637
0.230
 Why?
Enzyme Inhibitors
1
2006
374
0.230
 Why?
Female
11
2020
27188
0.220
 Why?
Survival Rate
2
2018
909
0.210
 Why?
Prostatic Neoplasms
1
2007
385
0.210
 Why?
Humans
16
2020
50688
0.210
 Why?
Follow-Up Studies
3
2019
2246
0.200
 Why?
Camptothecin
1
2002
15
0.200
 Why?
Male
10
2020
25998
0.190
 Why?
Antineoplastic Agents, Phytogenic
1
2002
66
0.190
 Why?
Lung Neoplasms
1
2007
599
0.180
 Why?
Diabetes Mellitus, Type 2
1
2007
515
0.180
 Why?
Oximes
1
2020
12
0.180
 Why?
Pyrimidinones
1
2020
19
0.180
 Why?
Pyridones
1
2020
34
0.170
 Why?
Thalidomide
1
2002
376
0.160
 Why?
Imidazoles
1
2020
128
0.160
 Why?
Cholangiocarcinoma
2
2011
25
0.160
 Why?
Protein Kinase Inhibitors
1
2020
205
0.150
 Why?
Survival Analysis
3
2020
661
0.140
 Why?
Antineoplastic Agents
2
2019
1173
0.140
 Why?
Melanoma
1
2020
280
0.140
 Why?
Neoplasm Staging
2
2013
743
0.130
 Why?
Combined Modality Therapy
1
2018
642
0.130
 Why?
Severity of Illness Index
1
2019
982
0.130
 Why?
Antibodies, Monoclonal
1
2019
461
0.120
 Why?
Skin Neoplasms
1
2020
496
0.120
 Why?
Gene Amplification
1
2015
56
0.120
 Why?
Adenine
1
2014
31
0.120
 Why?
Genes, myc
1
2015
33
0.120
 Why?
Polycomb Repressive Complex 2
1
2015
46
0.120
 Why?
Retrospective Studies
3
2018
6298
0.120
 Why?
United States
3
2019
5012
0.110
 Why?
Piperidines
1
2014
99
0.110
 Why?
Gene Deletion
1
2015
261
0.110
 Why?
Registries
3
2007
566
0.110
 Why?
Treatment Outcome
4
2020
5296
0.110
 Why?
Quinazolines
1
2013
33
0.100
 Why?
Leukemia, Myeloid, Acute
1
2015
181
0.100
 Why?
Actinomyces
1
2012
10
0.100
 Why?
Gene Expression Regulation, Neoplastic
1
2016
833
0.100
 Why?
Endoscopy, Gastrointestinal
1
2012
75
0.100
 Why?
Comorbidity
2
2019
626
0.090
 Why?
Gallbladder Neoplasms
1
2011
7
0.090
 Why?
Antibodies, Monoclonal, Humanized
1
2013
225
0.090
 Why?
Phenylurea Compounds
2
2011
15
0.090
 Why?
Niacinamide
2
2011
23
0.090
 Why?
Incidence
2
2019
1036
0.090
 Why?
Neoplasms
1
2019
1250
0.080
 Why?
Necrosis
1
2007
174
0.070
 Why?
Drugs, Investigational
1
2007
14
0.070
 Why?
Causality
1
2007
47
0.070
 Why?
Hospitals, University
1
2007
75
0.070
 Why?
Confidence Intervals
1
2007
155
0.070
 Why?
Tomography, X-Ray Computed
1
2012
1169
0.070
 Why?
Neoplasm Metastasis
2
2011
230
0.070
 Why?
Probability
1
2007
164
0.070
 Why?
Age Distribution
1
2007
173
0.070
 Why?
United States Food and Drug Administration
1
2007
91
0.070
 Why?
Anti-Bacterial Agents
1
2012
754
0.070
 Why?
Medical Oncology
1
2007
99
0.060
 Why?
Syndrome
1
2006
237
0.060
 Why?
Patient Selection
1
2007
259
0.060
 Why?
Publication Bias
1
2005
11
0.060
 Why?
Editorial Policies
1
2005
11
0.060
 Why?
Periodicals as Topic
1
2005
58
0.060
 Why?
Dose-Response Relationship, Drug
1
2007
1376
0.050
 Why?
Risk Assessment
1
2007
1271
0.050
 Why?
MAP Kinase Kinase Kinases
1
2020
19
0.040
 Why?
Socioeconomic Factors
1
2003
594
0.040
 Why?
Proto-Oncogene Proteins B-raf
1
2020
80
0.040
 Why?
Mutation, Missense
1
2020
103
0.040
 Why?
Drug Administration Schedule
1
2020
373
0.040
 Why?
Trisaccharides
1
2019
1
0.040
 Why?
Premedication
1
2019
17
0.040
 Why?
Administration, Oral
1
2020
438
0.040
 Why?
Magnetic Resonance Imaging
1
2006
1556
0.040
 Why?
Antibodies
1
2019
152
0.040
 Why?
Infusions, Intravenous
1
2019
213
0.040
 Why?
Health Services Accessibility
1
2003
426
0.040
 Why?
Disease Management
1
2019
179
0.040
 Why?
Arkansas
1
2003
1978
0.030
 Why?
Adolescent
1
2007
6489
0.030
 Why?
In Situ Hybridization, Fluorescence
1
2015
231
0.030
 Why?
Polymorphism, Single Nucleotide
1
2015
474
0.020
 Why?
Young Adult
1
2020
4114
0.020
 Why?
Disease-Free Survival
1
2011
442
0.020
 Why?
Govindarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (127) concept(s)
_
Co-Authors Expand Description
See all (1) people
_
Similar People Expand Description
See all (33) people
_
Same Department Expand Description
Search Department